Navigation Links
HealthEconomics.Com’s Pharma Pricing and Reimbursement Stories in This Week’s Newsletter
Date:4/1/2013

Ponte Vedra Beach, Florida (PRWEB) April 01, 2013

The top read story this week on HealthEconomics.Com was from a Healthy Criticism Blog posting by Nick Emptage, exploring why price transparency in pharmaceuticals and healthcare won’t reduce healthcare spending. Economist Emptage reflected on the business model of San Francisco-based Castlight Health, a company which contracts with employers to make the costs of health services transparent to employees. The idea is that employees will then lean toward lower-cost providers. Nick's blog points out the flaws of this idea as it relates to the health care market.

Another story of interest relates to comments by Jon Sussex, a member of the United Kingdom-based Office of Health Economics (OHE) Commission on Competition in the National Health Service (NHS). Sussex reflects on the revised draft of regulations to govern competition among providers of health care funded by the NHS in England; the first draft was replaced due to wide criticism. The article includes comments relating to the required use of competition by NHS in obtaining health care services for their populations unless there are good reasons not to do so.

The third most popular story on HealthEconomics.Com explored whether US taxpayers enjoy lower drug prices if federal money backed development. This question was based on actions by Senator Ron Wyden (Oregon-D), who has delved into this issue to explore the return-on-investment to the public based on tax dollar use for drug development. Should some of that return come in the form of lower prices on drugs developed with federal support? Original article sourced from FiercePharma.

About HealthEconomics.Com (http://www.healtheconomics.com):
A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and pharma market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.

News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by subscribing to the HealthEconomics.Com Newsletter.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10586528.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Myrtle Beach, SC (PRWEB) , ... April 26, ... ... for the mind, has teamed up with NASA to showcase the future of ... NASA’s Space Launch System (SLS) rocket and Orion spacecraft and includes a guest ...
(Date:4/26/2017)... RESTON, Va. (PRWEB) , ... April 26, 2017 ... ... to make headlines and drive high-level conversations among healthcare industry stakeholders, the discussion ... Healthcare Environment – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted ...
(Date:4/25/2017)... PROVIDENCE, R.I. , April 25, 2017 /PRNewswire/ ... EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology ... in autoimmune disease and allergy. Tregitopes, ... discovered in human immunoglobulin by EpiVax CEO ... Martin. Similar to intravenous immunoglobulin G, an autoimmune ...
(Date:4/24/2017)... April 24, 2017  Dante Labs announced today the offer ... 850 (ca. $900). While American individuals have been able to ... Europeans can access WGS below EUR 1,000. The ... leveraging genetic information to make informed decisions about disease monitoring, ... ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):